Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share Price

Price 13,674.00p on 26-12-2025 at 05:12:22
Change 0.00p 0%
Buy 13,666.00p
Sell 13,658.00p
Last Trade: Sell 12.00 at 13,674.00p
Day's Volume: 0
Last Close: 13,674.00p
Open: 0.00p
ISIN: GB0009895292
Day's Range 0.00p - 0.00p
52wk Range: 9,574.00p - 14,206.00p
Market Capitalisation: £211.99b
VWAP: 0.00p
Shares in Issue: 1.55b

Astrazeneca (AZN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 12 13,674.00p Automatic Execution
12:39:12 - 24-Dec-25
Buy* 75 13,674.00p SI Trade
12:35:02 - 24-Dec-25
Buy* 9 13,674.00p SI Trade
12:35:02 - 24-Dec-25
Unknown* 158,060 13,742.00p OTC Trade
12:30:45 - 24-Dec-25
Unknown* 158,060 13,742.00p OTC Trade
12:30:44 - 24-Dec-25
Sell* 47 13,660.00p Automatic Execution
12:30:00 - 24-Dec-25
Sell* 9 13,658.00p Automatic Execution
12:29:58 - 24-Dec-25
Sell* 12 13,660.00p Automatic Execution
12:29:57 - 24-Dec-25
Buy* 17 13,666.00p Automatic Execution
12:29:56 - 24-Dec-25
Buy* 32 13,666.00p Automatic Execution
12:29:56 - 24-Dec-25
See more Astrazeneca trades

Astrazeneca (AZN) Share Price History

Time period:
to
Date Open High Low Close Volume
26th Dec 2025 (Fri) 13,674.00 13,674.00 13,674.00 13,674.00 0
25th Dec 2025 (Thu) 13,674.00 13,674.00 13,674.00 13,674.00 0
24th Dec 2025 (Wed) 13,742.00 13,742.00 13,612.00 13,674.00 688,169
23rd Dec 2025 (Tue) 13,612.00 13,806.00 13,604.00 13,736.00 1,082,889
22nd Dec 2025 (Mon) 13,592.00 13,632.00 13,476.00 13,632.00 1,451,074
19th Dec 2025 (Fri) 13,574.00 13,714.00 13,508.00 13,672.00 10,404,455
18th Dec 2025 (Thu) 13,500.00 13,594.00 13,376.00 13,548.00 4,515,814
17th Dec 2025 (Wed) 13,574.00 13,682.00 13,534.00 13,554.00 2,468,738
16th Dec 2025 (Tue) 13,744.00 13,836.00 13,448.00 13,506.00 3,264,005
15th Dec 2025 (Mon) 13,412.00 13,638.00 13,376.00 13,612.00 2,467,612
12th Dec 2025 (Fri) 13,502.00 13,536.00 13,362.00 13,444.00 1,443,553
11th Dec 2025 (Thu) 13,618.00 13,686.00 13,488.00 13,596.00 1,284,513
10th Dec 2025 (Wed) 13,482.00 13,848.00 13,472.00 13,514.00 2,485,716
9th Dec 2025 (Tue) 13,758.00 13,794.00 13,568.00 13,592.00 1,232,388
8th Dec 2025 (Mon) 13,580.00 13,702.00 13,478.00 13,578.00 3,939,445
5th Dec 2025 (Fri) 13,560.00 13,688.00 13,542.00 13,592.00 1,500,908
4th Dec 2025 (Thu) 13,612.00 13,660.00 13,452.00 13,514.00 1,868,284
3rd Dec 2025 (Wed) 13,698.00 13,826.00 13,598.00 13,694.00 1,966,393
2nd Dec 2025 (Tue) 13,714.00 13,820.00 13,648.00 13,800.00 1,678,650
1st Dec 2025 (Mon) 13,966.00 14,092.00 13,800.00 13,836.00 1,952,001
28th Nov 2025 (Fri) 14,002.00 14,054.00 13,920.00 13,974.00 1,719,003
27th Nov 2025 (Thu) 14,070.00 14,158.00 13,940.00 14,012.00 1,037,045
See more Astrazeneca price history

Astrazeneca (AZN) Share News

LONDON MARKET CLOSE: FTSE fails to sparkle in tame pre-holiday trade

24th Dec 2025 13:14

(Alliance News) - The FTSE 100 drifted lower on Wednesday in lacklustre trading ahead of the Christmas break, although a chunky disposal by BP brought some life to proceedings. Read More

LONDON MARKET OPEN: FTSE mixed in shortened Christmas Eve trade

24th Dec 2025 09:17

(Alliance News) - Stock prices in London opened modestly lower on Wednesday, during a shortened trading session ahead of the Christmas holiday break. Read More

AstraZeneca says lung cancer trial fails to meet survival target

22nd Dec 2025 09:11

(Alliance News) - AstraZeneca PLC on Monday said a phase three trial in a potential treatment for a form of non-small cell lung cancer failed to meet a key aim, while its early breast cancer drug has been granted a breakthrough therapy designation in the US. Read More

LONDON BRIEFING: Harbour Energy makes USD3.2 billion US buy

22nd Dec 2025 07:52

(Alliance News) - Harbour Energy has struck a deal to deliver on a "long-standing ambition", while AstraZeneca reports a drug failed to meet its primary endpoint in a phase three trial, while another got breakthrough therapy designation in the US. Read More

Daiichi Sankyo, AstraZeneca apply for second EU approval for Datroway

18th Dec 2025 12:27

(Alliance News) - Daiichi Sankyo Co Ltd on Thursday said the EU has validated an application for Datroway as a first-line treatment for patients with metastatic triple negative breast cancer who are not candidates for immunotherapy. Read More

See more Astrazeneca news
FTSE 100 Latest
Value9,870.68
Change-18.54

Login to your account

Forgot Password?

Not Registered